Safety outcomes of SARS-CoV-2 vaccination in pediatric patients with a first dose reaction history or allergy to polyethylene glycol or polysorbate

Authors

Stella P. Hartono, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Disease, National Institute of Health, Bethesda, Md.
Hemant P. Sharma, Division of Allergy and Immunology, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC.
Vanessa Bundy, Division of Allergy and Immunology, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC.
Jessica D. Thompkins, Division of Allergy and Immunology, Children's National Hospital, Washington, DC.
Suzanne R. Kochis, Division of Allergy and Immunology, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC.
Joel P. Brooks, Division of Allergy and Immunology, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC. Electronic address: joelpbrooks@gmail.com.

Document Type

Journal Article

Publication Date

7-4-2022

Journal

The journal of allergy and clinical immunology. In practice

DOI

10.1016/j.jaip.2022.05.035

APA Citation

Hartono, Stella P.; Sharma, Hemant P.; Bundy, Vanessa; Thompkins, Jessica D.; Kochis, Suzanne R.; and Brooks, Joel P., "Safety outcomes of SARS-CoV-2 vaccination in pediatric patients with a first dose reaction history or allergy to polyethylene glycol or polysorbate" (2022). GW Authored Works. Paper 1362.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1362

Department

Pediatrics